Contact Lens Spectrum

July 2009

Document #164

 

References

 

 

(p. 14) Research Review: Essential Fatty Acids and Dry Eye: What Do We Know? By Lyndon Jones, PhD, FCOptom, FAAO

 

 

1.         The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5;2:  75-92.

2.         Marsh P, Pflugfelder SC: Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology 1999; 106;4:  811-816.

3.            Avunduk AM, Avunduk MC, et al.: The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol 2003; 136;4:  593-602.

4.         Perry HD, Donnenfeld ED: Topical 0.05% cyclosporin in the treatment of dry eye. Expert Opin Pharmacother 2004; 5;10:  2099-2107.

5.            Pflugfelder SC: Antiinflammatory therapy for dry eye. Am J Ophthalmol 2004; 137;2:  337-342.

6.            Fitzpatrick K: Essential fatty acids: Report to the Natural Health Products Directorate, Health Canada. Accessed May 2nd 2009. http://www.hc-sc.gc.ca/dhp-mps/pubs/natur/efa_age-eng.php 2005.

7.         Lands WE: Dose-response relationships for omega 3/omega 6 effects. World Rev Nutr Diet 1991; 66 177-194.

8.         Lands WE: Biochemistry and physiology of n-3 fatty acids. Faseb J 1992; 6;8:  2530-2536.

9.         Lands WE: Dietary fat and health: the evidence and the politics of prevention: careful use of dietary fats can improve life and prevent disease. Ann N Y Acad Sci 2005; 1055 179-192.

10.            Simopoulos AP: The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother 2002; 56;8:  365-379.

11.            Simopoulos AP: Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002; 21;6:  495-505.

12.            Simopoulos AP: Essential fatty acids in health and chronic diseases. Forum Nutr 2003; 56 67-70.

13.            Simopoulos AP: The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med (Maywood) 2008; 233;6:  674-688.

14.       Belch JJ, Hill A: Evening primrose oil and borage oil in rheumatologic conditions. Am J Clin Nutr 2000; 71;1 Suppl:  352S-356S.

15.       Das UN: Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules. Lipids Health Dis 2008; 7 37.

16.       Kapoor R, Huang YS: Gamma linolenic acid: an antiinflammatory omega-6 fatty acid. Curr Pharm Biotechnol 2006; 7;6:  531-534.

17.       Zurier RB, Rossetti RG, et al.: gamma-Linolenic acid treatment of rheumatoid arthritis. A randomized, placebo-controlled trial. Arthritis Rheum 1996; 39;11:  1808-1817.

18.       Oxholm P, Asmussen K, et al.: Essential fatty acid status in cell membranes and plasma of patients with primary Sjogren's syndrome. Correlations to clinical and immunologic variables using a new model for classification and assessment of disease manifestations. Prostaglandins Leukot Essent Fatty Acids 1998; 59;4:  239-245.

19.            Miljanovic B, Trivedi KA, et al.: Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in women. Am J Clin Nutr 2005; 82;4:  887-893.

20.            Barabino S, Rolando M, et al.: Systemic linoleic and gamma-linolenic acid therapy in dry eye syndrome with an inflammatory component. Cornea 2003; 22;2:  97-101.

21.            Aragona P, Bucolo C, et al.: Systemic omega-6 essential fatty acid treatment and pge1 tear content in Sjogren's syndrome patients. Invest Ophthalmol Vis Sci 2005; 46;12:  4474-4479.

22.       Kokke KH, Morris JA, et al.: Oral omega-6 essential fatty acid treatment in contact lens associated dry eye. Cont Lens Anterior Eye 2008; 31;3:  141-146; quiz 170.

23.       Macri A, Giuffrida S, et al.: Effect of linoleic acid and gamma-linolenic acid on tear production, tear clearance and on the ocular surface after photorefractive keratectomy. Graefes Arch Clin Exp Ophthalmol 2003; 241;7:  561-566.

24.       Macsai MS: The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). Trans Am Ophthalmol Soc 2008; 106 336-356.

25.       Pinna A, Piccinini P, et al.: Effect of oral linoleic and gamma-linolenic acid on meibomian gland dysfunction. Cornea 2007; 26;3:  260-264.

26.       Rashid S, Jin Y, et al.: Topical omega-3 and omega-6 fatty acids for treatment of dry eye. Arch Ophthalmol 2008; 126;2:  219-225.

27.            Hughner RS, Maher JK, et al.: Review of food policy and consumer issues of mercury in fish. J Am Coll Nutr 2008; 27;2:  185-194.

28.            Domingo JL: Omega-3 fatty acids and the benefits of fish consumption: is all that glitters gold? Environ Int 2007; 33;7:  993-998.

29.       Smith KM, Sahyoun NR: Fish consumption: recommendations versus advisories, can they be reconciled? Nutr Rev 2005; 63;2:  39-46.

30.            McClaskey EM, Michalets EL: Subdural hematoma after a fall in an elderly patient taking high-dose omega-3 fatty acids with warfarin and aspirin: case report and review of the literature. Pharmacotherapy 2007; 27;1:  152-160.

31.            Vanschoonbeek K, de Maat MP, et al.: Fish oil consumption and reduction of arterial disease. J Nutr 2003; 133;3:  657-660.

 

 

(p. 19) GP Insights: The Benefits of Scleral Lenses for Graft Versus Host Disease, By Ann Laurenzi, OD, FAAO

 

  1. Jacobs DS, Rosenthal P., Boston scleral lens prosthetic device for treatment of severe dry eye in chronic graft versus host disease.  Cornea. 2007 Dec;26(10): 1195-9.
  2. SchornackMM,BaratzKH, Patel SV, Maguire LJ., Jupiter scleral lenses in the management of chronic graft versus host disease.  Eye Contact Lens. 2008 Nov;34(6): 302-5.
  3. TakahideK, et al., Use of fluid-ventilated, gas-permeable scleral lens for management of severe keratoconjunctivitis sicca secondary to chronic graft-versus-host disease.  Biol Blood Marrow Transplant. 2007 Sept; 13 (9): 1016-21.
  4. Russo PA, Bouchard CS, Glasso JM., Extended-wear silicone hydroget soft contact lenses in the management of moderate to severe dry eye signs and symptoms secondary to graft-versus-host disease. Eye Contact Lens.  2007 May; 33 (3): 144-7.
  5. Franklin RM et al., Ocular manifestations of graft-versue-host disease.  Ophthalmology. 1983 Jan; 90 (1): 4-13.
  6. Claes K, Kestelyn P., Ocular manifestations of graft versus host disease following bone marrow transplantation.  2000 Bull. Soc. Belge ophtalmol., 277, 21-26.

 

 

 

(p. 26) 2009 Annual Report on Dry Eye Diseases, By Jason J. Nichols, OD, MPH, PhD, FAAO

 

1.                Lemp MA, Nichols KK. Blepharitis in the United States 2009: A Survey-based Perspective on Prevalence and Treatment. Ocul Surf 2009;7:S1-S14.

2.                Smith JA, Albeitz J, Begley C et al. The epidemiology of dry eye disease: Report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5:93-107.

3.                Schaumberg DA, Dana R, Buring JE, Sullivan DA. Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies. Arch Ophthalmol 2009;127:763-8.

4.                Lekhanont K, Rojanaporn D, Chuck RS, Vongthongsri A. Prevalence of Dry Eye in Bangkok, Thailand. Cornea 2006;25:1162-1167.

5.                Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol 2003;136:318-26.

6.                Lin PY, Tsai SY, Cheng CY, Liu JH, Chou P, Hsu WM. Prevalence of dry eye among an elderly Chinese population in Taiwan: The Shihpai Eye Study. Ophthalmology 2003;110:1096-1101.

7.                Chia EM, Mitchell P, Rochtchina E, Lee AJ, Maroun R, Wang JJ. Prevalence and associations of dry eye syndrome in an older population: the Blue Mountains Eye Study. Clin Experiment Ophthalmol 2003;31:229-32.

8.                McCarty CA, Bansal AK, Livingston PM, Stanislavsky YL, Taylor HR. The epidemiology of dry eye in Melbourne, Australia. Ophthalmology 1998;105:1114-9.

9.                Schein OD, Munoz B, Tielsch JM, Bandeen-Roche K, West S. Prevalence of dry eye among the elderly. Am J Ophthalmol 1997;124:723-8.

10.           Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol 2000;118:1264-8.

11.           Korb DR. Survey of preferred tests for diagnosis of the tear film and dry eye. Cornea 2000;19:483-6.

12.           Nichols KK, Nichols JJ, Zadnik K. Frequency of dry eye diagnostic test procedures used in various modes of ophthalmic practice. Cornea 2000;19:477-82.

13.           Nichols JJ, Ziegler C, Mitchell GL, Nichols KK. Self-reported dry eye disease across refractive modalities. Invest Ophthalmol Vis Sci 2005;46:1911-4.

14.           Begley CG, Chalmers RL, Mitchell GL et al. Characterization of ocular surface symptoms from optometric practices in North America. Cornea 2001;20:610-8.

15.           Begley CG, Caffery B, Nichols KK, Chalmers R. Responses of contact lens wearers to a dry eye survey. Optom Vis Sci 2000;77:40-6.

16.            Caffery BE, Richter D, Simpson T, Fonn D, Doughty M, Gordon K. CANDEES. The Canadian Dry Eye Epidemiology Study. Adv Exp Med Biol 1998;438:805-6.

 

(p. 32) Inflammation in Dry Eye Disease, By Paul Karpecki, OD, FAAO

 

1.        [1] Lemp MA.  Evaluation and differential diagnosis of keratoconjunctivitis sicca.  J Rheumatol Suppl.  2000 Dec;61:11-4

2.        [1] Stern ME, Beuerman RW, Fox RI et al.  The pathology od dry eye: the interaction between the ocular surface and lacrimal glands.  Cornea.  1998 Nov;17(6):584-9

3.        [1] Pflugfelder SC.  Antiinflammatory therapy for dry eye.  Am J Ophthalmol.  2004 Feb;137(2):337-42

4.        [1] Rao, S. Clinical Study Report: Topical Cyclosporine 0.05% for the Prevention of Dry Eye Disease Progression. 2008

5.        [1] Schaumberg DA, Gulati A, Mathers WD et al.  Development and validation of a short global dry eye symptom index.  Ocular Surface.  2007 Jan;5(1):50-7

6.        [1] Moss SE, Klein R, Klein BE.  Incidence of dry eye in an older population.  Archives Ophthalmology.  2004 Mar;122(3):369-73 

7.        [1] Nichols JJ, Ziegler C, Mithcell GL, Nichols KK.  Self-reported dry eye disease across refractive modalities.  Invest Ophthalmol Vis Sci.  2005 Jun;46(6):1911-4

8.        [1] Lois N, Abdelkader E, Reglitz K et al.  Environmental tobacco smoke exposure and eye disease.  British Journal of Ophthalmology  2008;July 25

9.       [1] The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf. 2007 Apr;5(2):75-92. Review.

10.     [1] Schaumberg DA, Buring JE, Sullivan DA et al.  Hormone replacement therapy and dry eye syndrome.  JAMA.   2001 Nov 7;286(17):2114-9

11.     [1] Schaumberg DA, Sullivan DA, Dana MR.  Epidemiology of dry eye syndrome.  Adv Exp Med Biol.  2002;506:989-98

12.     [1] Hom MM, Simmons PA, Vehige J.  Correspondence of tear film osmolarity and dry eye symptoms in a clinical setting.  Poster presented at the American Academy of Optometry; Tampa FL, October 26, 2007

13.     [1] Luo L, Li DQ, Corrales RM et al.  Hyperosmoloar saline is a proinflammatory stress on the mouse ocular surface.  Eye Contact Lens.  2005 Sep;31(5):186-93

14.     [1] Yokoi N, Mossa F, Tiffany JM et al.  Assessment of Meibomian gland function in dry eye using meibometry.  Archives Ophthalmology.  1999 Jun;117(6):723-9

15.     [1] Baudouin C.  The pathology od dry eye.  Survey of Ophthalmology.  2001 Mar;45 Suppl 2:S211-20

16.     [1] Gilbard JP.  Dry eye, blepharitis and chronic eye irritation: divide and conquer.  J Ophthalmic Nurse Technology.  2999 May-Jun;18(3):109-15

17.     [1] Luchs J.,  Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis.  Adv Ther.  2008 Sep;25(9):858-70

18.     [1] Jackson WB, Blepharitis: current strategies for diagnosis and management.  Can J Ophthalmology.  2008 Apr;43(2):170-9

19.     [1]Voils SA, Evans ME, Lane MT et al.  Use of macrolides and tetracyclines for chronic inflammatory disease.  Ann Pharmacother.  2005 Jan;39(1):86-94

20.     [1] Yoo SE, Lee DC, Chang MH.  The effect of low dose doxycycline therapy in chronic meibomian gland dysfunction.  Korean J Ophthalmology.  2005;19(4):258-263

21.     [1] Nelson JD, Helms H, Fiscella R, Southwell Y, Hirsch JD. A new look at dry eye disease and its treatment. Adv Ther. 2000;17(2):84-93

22.     [1] Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea. 1998;17(6):584-589.

23.     [1] Kunert KS, Tisdale AS, Stern ME, Smith JA, Gipson IK. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol. 2000;118(11):1489-1496.

24.     [1] Sall K, Stevenson OD, Mundorf TK, Reis BL; CsA Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology. 2000;107(4):631-639

25.     [1] Rao, S. Clinical Study Report: Topical Cyclosporine 0.05% for the Prevention of Dry Eye Disease Progression. 2008

26.     [1] Behrens A, Doyle JJ, Stern L, et al; Dysfunctional tear syndrome study group. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations.  Cornea. 2006;25(8):900-907

27.     [1] Perry HD, Solomon R, Donnenfeld ED, et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol. 2008;126(8):1046-1050

28.     [1] Sall K, Stevenson OD, Mundorf TK, Reis BL; CsA Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease [published correction appears in Ophthalmology. 2000;107(7):1220]. Ophthalmology. 2000;107(4):631-639.

29.     [1] Sall K, Stevenson OD, Mundorf TK, Reis BL; CsA Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease [published correction appears in Ophthalmology. 2000;107(7):1220]. Ophthalmology. 2000;107(4):631-639.

30.     [1] Brignole F, Pisella PJ, De Saint Jean M et al.  Flow cytometric analysis of inflammatory markers in KCS : 6 month treatment with topical cyclosporin A.  Invest Ophthalmol Vis Sci.  2001 Jan;42(1):90-5

31.     [1] Pflugfelder SC, De Paiva CS, Villarreal AL et al.  Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production.  Cornea.  2008 Jan;27(1):64-9

32.     [1] Sall K, Stevenson OD, Mundorf TK, Reis BL; CsA Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease [published correction appears in Ophthalmology. 2000;107(7):1220]. Ophthalmology. 2000;107(4):631-639.

33.     [1] Prabhasawat & Tseng,  BJO 1998

34.     [1] Marsh P, Pflugfelder SC.  Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogrens Syndrome.  Ophthalmology.  1999 Apr;106(4):811-6

35.     [1] Pflugfelder SC, Maskin SL, Anderson B et al.  A randomized, double-masked, placebo-controlled, multicetner comparison of loteprednol etabonate ophthalmic suspension 0.5% and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance.  Am J Ophthalmology.  2004 Sep;138(3):444-57

36.     [1] Dursun D, Kim MC, Solomon A et al.  Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline and corticosteroids.  American Journal of Ophthalmology.  2001 Jul;132(1):8-13

37.     [1] Yoo SE, Lee DC, Chang MH.  The effect of low dose doxycycline therapy in chronic meibomian gland dysfunction.  Korean J Ophthalmology.  2005;19(4):258-263

38.     [1] Laidlaw M, Holub BJ.  Effects of supplementation with fish oil-derived n-3 fatty acids and gamma-linolenic acid on circulating plasma lipids and fatty acid profiles in women.  American Journal of Clinical Nutrition.  2003 Jan;77(1):37-42

39.     [1] Aragona P, Bucolo C, Spinella R et al.  Systemic omega-6 essential fatty acid treatment and PGE1 tear content in Sjogren’s syndrome patients.  Investigative Ophthalmology and Visual Science.  2005 Dec 46:4474-9

40.     [1] Barabino S, Rolando M, Camicione P et al.  Systemic linoleic and gamma-linolenic acid therapy in dry eye syndrome with an inflammatory component.  Cornea.  Mar 2003 22:97-101

41.     [1] Scaffidi RC, Korb DR.  Comparison of the efficacy of two lipid emulsion eye drops in increasing tear film lipid layer thickness.  Eye Contact Lens.  2007 Jan;33(1):38-44

42.     [1] Korb DR, Scaffidi RC Greiner JV et al.  The effect of two novel lubricant eye drops on tear film lipid layer thickness in subjects with dry eye symptoms.  Optometry and Vis Science.  2005 Jul;82(7):594-601

43.     [1] Giovagnoli D, Graham SJ.  Journal of the American Optometric Association, 1992 July;63(7):481-5

44.     [1] Behrens A, Doyle JJ, Stern L et al.  Dysfunctional tear syndrome: a Delhi approach to treatment recommendations.  Cornea.  2006 Sep;25(8):900-7

45.     [1] Gao J, Morgan G Tieu D et al.  ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjogrens’ syndrome-like MRL/lpr mice.  Exp Eye Res.  2004 Apr;78(4):823-35

46.     [1] Moss SE, Klein R, Klein BE.  Prevalence of and risk factors for dry eye syndrome.  Arch Ophthalmol.  2000 Sep;118(9):1264-8

47.     [1] Moss SE, Klein R, Klein BE.  Long-term incidence of dry eye in an older population.  Optom Vis Sci.  2008 Aug;85(8):668-74

48.     [1] Schaumberg DA, Sullivan DA, Buring JE et al.  Prevalence of dry eye syndrome among US women.  Am J Ophthalmol.  2003 Aug;136;(2):318-26

49.     [1] Pflugfelder SC.  Prevalence, burden and pharmacoeconomics of dry eye disease.  Am J Managed Care.   2008 Apr;14(3 Suppl):S102-6

 

 

 

(p. 39) What Influences Contact Lens-Related Dry Eye? By Lakshman N. Subbaraman, PhD, BSOptom, MSc, FAAO, & Lyndon Jones, PhD, FCOptom, DipCLP, DipOrth, FAAO (Dip CL), FIACLE

 

1.         Nichols JJ, Mitchell GL, Nichols KK, Chalmers R, Begley C. The performance of the contact lens dry eye questionnaire as a screening survey for contact lens-related dry eye. Cornea 2002; 21: 469-475.

2.         Begley CG, Chalmers RL, Mitchell GL, Nichols KK, Caffery B, Simpson T, DuToit R, Portello J, Davis L. Characterization of ocular surface symptoms from optometric practices in North America. Cornea 2001; 20: 610-618.

3.         Begley CG, Caffery B, Nichols KK, Chalmers R. Responses of contact lens wearers to a dry eye survey. Optom Vis Sci 2000; 77: 40-46.

4.         The definition and classification of dry eye disease: report of the definition and classification subcommittee of the International Dry Eye WorkShop. Ocul Surf 2007; 5: 75-92.

5.            Epidemiology of dry eye: Report of the epidemiology subcommittee of the 2007 Dry Eye WorkShop (DEWS). Ocul Surf 2007; 5: 93-107.

6.            Methodologies to diagnose and monitor dry eye. Report of the diagnostic subcommittee of the International Dry Eye WorkShop. Ocul Surf 2007; 5: 108-152.

7.            Doughty MJ, Fonn D, Richter D, Simpson T, Caffery B, Gordon K. A patient questionnaire approach to estimating the prevalence of dry eye symptoms in patients presenting to optometric practices across Canada. Optom Vis Sci 1997; 74: 624-631.

8.            Pritchard N, Fonn D, Brazeau D. Discontinuation of contact lens wear: a survey. Int Contact Lens Clin 1999; 26: 157-162.

9.         Nichols JJ, Ziegler C, Mitchell GL, Nichols KK. Self-reported dry eye disease across refractive modalities. Invest Ophthalmol Vis Sci 2005; 46: 1911-1914.

10.       Guillon M, Styles E, Guillon JP, Maissa C. Preocular tear film characteristics of non-wearers and soft contact lens wearers. Optom Vis Sci 1997; 74: 273-279.

11.            Richdale K, Sinnott LT, Skadahl E, Nichols JJ. Frequency of and factors associated with contact lens dissatisfaction and discontinuation. Cornea 2007; 26: 168-174.

12.       Young G, Veys J, Pritchard N, Coleman S. A multi-centre study of lapsed contact lens wearers. Ophthalmic Physiol Opt 2002; 22: 516-527.

13.            Ramamoorthy P, Sinnott LT, Nichols JJ. Treatment, material, care, and patient-related factors in contact lens-related dry eye. Optom Vis Sci 2008; 85: 764-772.

14.       Efron N, Brennan N. A survey of wearers of low water content hydrogel contact lenses. Clin Exp Optom 1988; 71: 86 - 90.

15.       Efron N, Young G. Dehydration of hydrogel contact lenses in vitro and in vivo. Ophthal Physiol Opt 1988; 8: 253 - 256.

16.       Holden B, Sweeney D, Seger R. Epithelial erosions caused by thin high water content lenses. Clin Exp Optom 1986; 69: 103-107.

17.            Pritchard N, Fonn D. Dehydration, lens movement and dryness ratings of hydrogel contact lenses. Ophthal Physiol Opt 1995; 15: 281-286.

18.            Orsborn GN, Zantos SG. Corneal desiccation staining with thin high water content contact lenses. CLAO J 1988; 14: 81-85.

19.            Andrasko G, Schoessler J. The effect of humidity on the dehydration of soft contact lenses on the eye. Int Contact Lens Clin 1980; 7: 30-33.

20.            Brennan N, Efron N, Bruce A, Duldig D, Russo N. Dehydration of hydrogel lenses: Environmental influences during normal wear. Am J Optom Physiol Opt 1988; 65: 277-281.

21.       Efron N, Brennan N, Bruce A, Duldig D, Russo N. Dehydration of hydrogel lenses under normal wearing conditions. CLAO J 1987; 13: 152-156.

22.       Jones L, May C, Nazar L, Simpson T. In vitro evaluation of the dehydration characteristics of silicone hydrogel and conventional hydrogel contact lens materials. Cont Lens Anterior Eye 2002; 25: 147-156.

23.            Gonzalez-Meijome JM, Lopez-Alemany A, Almeida JB, Parafita MA, Refojo MF. Qualitative and quantitative characterization of the in vitro dehydration process of hydrogel contact lenses. J Biomed Mater Res B Appl Biomater 2007; 83: 512-526.

24.       Larsen D, Huff J, Holden B. Proton NMR relaxation in hydrogel contact lenses: Correlation with in vivo lens dehydration data. Curr Eye Res 1990; 9: 697 - 706.

25.       Benz P, Ors J. New materials demand more accurate measurements of performance. Spectrum 1997: 40-46.

26.            Andrasko G. Hydrogel dehydration in various environments. Int Contact Lens Clin 1983; 10: 22 - 28.

27.            Wechsler S, Prather D, Sosnowski J. In vivo hydration of gel lenses. Int Contact Lens Clin 1982; 9: 154 - 158.

28.       Efron N, Morgan PB. Hydrogel contact lens dehydration and oxygen transmissibility. CLAO J 1999; 25: 148-151.

29.       Young G, Bowers R, Hall B, Port M. Six month clinical evaluation of a biomimetic hydrogel contact lens. CLAO J 1997; 23: 226-236.

30.       Fonn D, Situ P, Simpson T. Hydrogel lens dehydration and subjective comfort and dryness ratings in symptomatic and asymptomatic contact lens wearers. Optom Vis Sci 1999; 76: 700-704.

31.       Young G, Bowers R, Hall B, Port M. Clinical comparison of Omafilcon A with four control materials. CLAO J 1997; 23: 249-258.

32.       Hall B, Jones S, Young G, Coleman S. The on-eye dehydration of proclear compatibles lenses. CLAO J 1999; 25: 233-237.

33.            Quesnel NM, Giasson CJ. On-eye dehydration of proclear, resolution 55G and Acuvue contact lenses. Cont Lens Anterior Eye 2001; 24: 88-93.

34.            Bontempo AR, Rapp J. Protein and lipid deposition onto hydrophilic contact lenses in vivo. CLAO J 2001; 27: 75-80.

35.       Castillo EJ, Koenig JL, Anderson JM, Jentoft N. Protein adsorption on soft contact lenses. III. Mucin. Biomaterials 1986; 7: 9-16.

36.       Jones L, Evans K, Sariri R, Franklin V, Tighe B. Lipid and protein deposition of N-vinyl pyrrolidone-containing group II and group IV frequent replacement contact lenses. CLAO J 1997; 23: 122-126.

37.       Sack RA, Jones B, Antignani A, Libow R, Harvey H. Specificity and biological activity of the protein deposited on the hydrogel surface. Relationship of polymer structure to biofilm formation. Invest Ophthalmol Vis Sci 1987; 28: 842-849.

38.       Gellatly KW, Brennan NA, Efron N. Visual decrement with deposit accumulation of HEMA contact lenses. Am J Optom Physiol Opt 1988; 65: 937-941.

39.       Jones L, Franklin V, Evans K, Sariri R, Tighe B. Spoilation and clinical performance of monthly vs three monthly group II disposable contact lenses. Optom Vis Sci 1996; 73: 16-21.

40.       Fonn D, Dumbleton K. Dryness and discomfort with silicone hydrogel contact lenses. Eye Contact Lens 2003; 29: S101-104; discussion S115-108, S192-104.

41.            Allansmith MR, Korb DR, Greiner JV, Henriquez AS, Simon MA, Finnemore VM. Giant papillary conjunctivitis in contact lens wearers. Am J Ophthalmol 1977; 83: 697-708.

42.            Porazinski AD, Donshik PC. Giant papillary conjunctivitis in frequent replacement contact lens wearers: a retrospective study. CLAO J 1999; 25: 142-147.

43.            Skotnitsky C, Sankaridurg PR, Sweeney DF, Holden BA. General and local contact lens induced papillary conjunctivitis (CLPC). Clin Exp Optom 2002; 85: 193 -197.

44.            Skotnitsky CC, Naduvilath TJ, Sweeney DF, Sankaridurg PR. Two presentations of contact lens-induced papillary conjunctivitis (CLPC) in hydrogel lens wear: Local and general. Optom Vis Sci 2006; 83: 27-36.

45.            Subbaraman LN, Glasier MA, Senchyna M, Sheardown H, Jones L. Kinetics of in vitro lysozyme deposition on silicone hydrogel, PMMA, and FDA groups I, II, and IV contact lens materials. Curr Eye Res 2006; 31: 787-796.

46.       Suwala M, Glasier MA, Subbaraman LN, Jones L. Quantity and conformation of lysozyme deposited on conventional and silicone hydrogel contact lens materials using an in vitro model. Eye Contact Lens 2007; 33: 138-143.

47.       Jones L, Mann A, Evans K, Franklin V, Tighe B. An in vivo comparison of the kinetics of protein and lipid deposition on group II and group IV frequent-replacement contact lenses. Optom Vis Sci 2000; 77: 503-510.

48.       Lorentz H, Jones L. Lipid deposition on hydrogel contact lenses: how history can help us today. Optom Vis Sci 2007; 84: 286-295.

49.       Jones L, Senchyna M, Glasier MA, Schickler J, Forbes I, Louie D, May C. Lysozyme and lipid deposition on silicone hydrogel contact lens materials. Eye Contact Lens 2003; 29: S75-79; discussion S83-74, S192-194.

50.            Senchyna M, Jones L, Louie D, May C, Forbes I, Glasier M. Quantitative and conformational characterization of lysozyme deposited on balafilcon and etafilcon contact lens materials. Curr Eye Res 2004; 28: 25-36.

51.            Subbaraman LN, Jones L, Srinivasan S, Varikooty J, Glasier M. Activity of lysozyme deposited on one-day etafilcon contact lenses is correlated with subjective comfort. Optom Vis Sci 2006; 83 E-abstract 060091.

52.            Pritchard N, Fonn D, Weed K. Ocular and subjective responses to frequent replacement of daily wear soft contact lenses. CLAO J 1996; 22: 53-59.

53.       Boswall GJ, Ehlers WH, Luistro A, Worrall M, Donshik PC. A comparison of conventional and disposable extended wear contact lenses. Clao J 1993; 19: 158-165.

54.            Marshall E, Begley C, Nguyen C. Frequency of complications among wearers of disposable and conventional soft contact lenses. Int Contact Lens Clin 1992; 19: 55-59.

55.       Poggio EC, Abelson M. Complications and symptoms in disposable extended wear lenses compared with conventional soft daily wear and soft extended wear lenses. CLAO J 1993; 19: 31-39.

56.       Patel S, Thomson A, Raj S. Tear film stability with planned replacement soft lenses. Optician 1996; 212: 28-30.

57.       Guillon J, Guillon M, Dwyer S, Mapstone V. Hydrogel lens in vivo wettability. J Brit Contact Lens Assoc Trans Ann Clin Conf 1989: 44-45.

58.       Guillon M, McGrogan L, Guillon J, Styles E, Maissa C. Effect of material ionicity on the performance of daily disposable contact lenses. Cont Lens Anterior Eye 1997; 20: 3-8.

59.       Lorentz H, Rogers R, Jones L. The impact of lipid on contact angle wettability. Optom Vis Sci 2007; 84: 946-953.

60.            Subbaraman LN, Bayer S, Glasier MA, Lorentz H, Senchyna M, Jones L. Rewetting drops containing surface active agents improve the clinical performance of silicone hydrogel contact lenses. Optom Vis Sci 2006; 83: 143-151.

61.            Brennan NA, Coles ML, Comstock TL, Levy B. A 1-year prospective clinical trial of balafilcon a (PureVision) silicone hydrogel contact lenses used on a 30-day continuous wear schedule. Ophthalmology 2002; 109: 1172-1177.

62.       Long B, McNally J. The clinical performance of a silicone hydrogel lens for daily wear in an Asian population. Eye Contact Lens 2006; 32: 65-71.

63.            Dumbleton K, Keir N, Moezzi A, Feng Y, Jones L, Fonn D. Objective and subjective responses in patients refitted to daily-wear silicone hydrogel contact lenses. Optom Vis Sci 2006; 83: 758-768.

64.            Chalmers RL, Dillehay S, Long B, Barr JT, Bergenske P, Donshik P, Secor G, Yoakum J. Impact of previous extended and daily wear schedules on signs and symptoms with high Dk lotrafilcon A lenses. Optom Vis Sci 2005; 82: 549-554.

65.            Chalmers RL, Hunt C, Hickson-Curran S, Young G. Struggle with hydrogel CL wear increases with age in young adults. Cont Lens Anterior Eye 2009; 32: 113-119.

66.            Sweeney D, du Toit R, etal. Clinical performance of silicone hydrogel lenses. In: Sweeney D. Silicone hydrogels: Continuous wear contact lenses. Oxford: Butterworth-Heinemann, 2004;   164-216.

67.       Fonn D, Pritchard N, Dumbleton K. Factors affecting the success of silicone hydrogels. In: Sweeney D. Silicone Hydrogels: The Rebirth of Continuous Wear Contact Lenses. Oxford, UK: Butterworth-Heinemann, 2000;   214 - 234.

68.            Brennan NA, Coles ML, Ang JH. An evaluation of silicone hydrogel lenses worn on a daily wear basis. Clin Exp Optom 2006; 89: 18-25.

69.       King-Smith PE, Nichols JJ, Nichols KK, Fink BA, Braun RJ. Contributions of evaporation and other mechanisms to tear film thinning and break-up. Optom Vis Sci 2008; 85: 623-630.

70.       Morgan PB, Efron N. In vivo dehydration of silicone hydrogel contact lenses. Eye Contact Lens 2003; 29: 173-176.

71.       Morgan PB, Efron N. Hydrogel contact lens ageing. CLAO J 2000; 26: 85-90.

72.       Nichols JJ, Sinnott LT. Tear film, contact lens, and patient-related factors associated with contact lens-related dry eye. Invest Ophthalmol Vis Sci 2006; 47: 1319-1328.

73.            Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol 2003; 136: 318-326.

74.            Schaumberg DA, Buring JE, Sullivan DA, Dana MR. Hormone replacement therapy and dry eye syndrome. JAMA 2001; 286: 2114-2119.

75.            Schaumberg DA, Sullivan DA, Dana MR. Epidemiology of dry eye syndrome. Adv Exp Med Biol 2002; 506: 989-998.

76.       Ladwig KH, Marten-Mittag B, Formanek B, Dammann G. Gender differences of symptom reporting and medical health care utilization in the German population. Eur J Epidemiol 2000; 16: 511-518.

77.       Page S. Perception of medical symptoms according to gender of reporting person and type of symptom. J Health Soc Policy 1997; 8: 57-66.

78.            Almeida SA, Trone DW, Leone DM, Shaffer RA, Patheal SL, Long K. Gender differences in musculoskeletal injury rates: a function of symptom reporting? Med Sci Sports Exerc 1999; 31: 1807-1812.

79.            Chalmers RL, Begley CG. Dryness symptoms among an unselected clinical population with and without contact lens wear. Cont Lens Anterior Eye 2006; 29: 25-30.

80.       Nichols JJ, King-Smith PE. Thickness of the pre- and post-contact lens tear film measured in vivo by interferometry. Invest Ophthalmol Vis Sci 2003; 44: 68-77.

81.       Willcox MD, Morris CA, Thakur A, Sack RA, Wickson J, Boey W. Complement and complement regulatory proteins in human tears. Invest Ophthalmol Vis Sci 1997; 38: 1-8.

82.       Willcox MD, Power KN, Stapleton F, Leitch C, Harmis N, Sweeney DF. Potential sources of bacteria that are isolated from contact lenses during wear. Optom Vis Sci 1997; 74: 1030-1038.

83.       Chang SW, Chang CJ. Delayed tear clearance in contact lens associated papillary conjunctivitis. Curr Eye Res 2001; 22: 253-257.

84.       Gilbard JP, Gray KL, Rossi SR. A proposed mechanism for increased tear-film osmolarity in contact lens wearers. Am J Ophthalmol 1986; 102: 505-507.

85.       Holly FJ, Refojo MF. Wettability of hydrogels. I. Poly (2-hydroxyethyl methacrylate). J Biomed Mater Res 1975; 9: 315-326.

86.       Guillon M, Maissa C, Styles E. Relationship between pre-ocular tear film structure and stability. Adv Exp Med Biol 1998; 438: 401-405.

87.       Glasson MJ, Stapleton F, Keay L, Willcox MD. The effect of short term contact lens wear on the tear film and ocular surface characteristics of tolerant and intolerant wearers. Cont Lens Anterior Eye 2006; 29: 41-47; quiz 49.

88.       Glasson M, Stapleton F, Willcox M. Lipid, lipase and lipocalin differences between tolerant and intolerant contact lens wearers. Curr Eye Res 2002; 25: 227-235.

89.       Glasson MJ, Stapleton F, Keay L, Sweeney D, Willcox MDP. Differences in clinical parameters and tear film of tolerant and intolerant contact lens wearers. Invest Ophthalmol Vis Sci 2003; 44: 5116-5124.

90.            Maruyama K, Yokoi N, Takamata A, Kinoshita S. Effect of environmental conditions on tear dynamics in soft contact lens wearers. Invest Ophthalmol Vis Sci 2004; 45: 2563-2568.

91.            Cedarstaff T, Tomlinson A. A comparative study of tear evaporation rates and water content of soft contact lenses. Am J Optom Physiol Opt 1983; 60: 167-174.

92.       Thai LC, Tomlinson A, Doane MG. Effect of contact lens materials on tear physiology. Optom Vis Sci 2004; 81: 194-204.

93.       Tonge S, Tighe B, Franklin V, Bright A. Contact lens care, Part 6: Comfort drops, artificial tears and dry-eye therapies. Optician 2001; 222: 27-32.

94.       Jones L, Senchyna M. Soft contact lens solutions review Part 1: Components of modern care regimens. Optometry in Practice 2007; 8: 45-56.

95.            Stiegemeier MJ, Friederichs GJ, Hughes JL, Larsen S, Movic W, Potter WB. Clinical evaluation of  new multi-purpose disinfecting solution in symptomatic contact lens wearers. Cont Lens Anterior Eye 2006.

 

 

 

 

 

(p. 48) Pediatric and Teen CL Care: Dry Eyes Are Less of a Problem in Young Contact Lens Wearers, By Jeffrey J. Walline, OD, PhD, & Marjorie J. Rah, OD, PhD

 

1.                 1.       Doughty MJ, Fonn D, Richter D, Simpson T, Caffery B, Gordon K. A patient questionnaire approach to estimating the prevalence of dry eye symptoms in patients presenting to optometric practices across Canada. Optom Vis Sci 1997;74:624-31.

2.                 2.       Begley CG, Chalmers RL, Mitchell GL, Nichols KK, Caffery B, Simpson T, DuToit R, Portello J, Davis L. Characterization of ocular surface symptoms from optometric practices in North America. Cornea 2001;20:610-8.

3.                 3.       Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol 2003;136:318-26.

4.                 4.       Shimmura S, Shimazaki J, Tsubota K. Results of a population-based questionnaire on the symptoms and lifestyles associated with dry eye. Cornea 1999;18:408-11.

5.                 5.       Lemp MA. Advances in understanding and managing dry eye disease. Am J Ophthalmol 2008;146:350-6.

6.                 6.       Fonn D. Targeting contact lens induced dryness and discomfort: what properties will make lenses more comfortable. Optom Vis Sci 2007;84:279-85.

7.                 7.       Richdale K, Sinnott LT, Skadahl E, Nichols JJ. Frequency of and factors associated with contact lens dissatisfaction and discontinuation. Cornea 2007;26:168-74.

8.                 8.       Hom M, De Land P. Prevalence and severity of symptomatic dry eyes in Hispanics. Optom Vis Sci 2005;82:206-8.

9.                 9.       Greiner KL, Walline JJ. Dryness Report in Pediatrics (DRIP) Study. Optometry and Vision Science 2006;83:E-abstract: 06004.

10.             10.       Nichols JJ, Mitchell GL, Nichols KK. An assessment of self-reported disease classification in epidemiological studies of dry eye. Invest Ophthalmol Vis Sci 2004;45:3453-7.

11.             11.       Alves M, Dias AC, Rocha EM. Dry eye in childhood: epidemiological and clinical aspects. Ocul Surf 2008;6:44-51.

12.             12.       Akinci A, Cakar N, Uncu N, Kara N, Acaroglu G. Keratoconjunctivitis sicca in juvenile rheumatoid arthritis. Cornea 2007;26:941-4.

13.             13.       Akinci A, Cetinkaya E, Aycan Z. Dry eye syndrome in diabetic children. Eur J Ophthalmol 2007;17:873-8.

14.             14.       Walline JJ, Long S, Zadnik K. Daily disposable contact lens wear in myopic children. Optom Vis Sci 2004;81:255-9.

15.             15.       Walline JJ, Rah MJ, Jones LA. The Children's Overnight Orthokeratology Investigation (COOKI) pilot study. Optom Vis Sci 2004;81:407-13.

16.             16.       Walline JJ, Gaume A, Jones LA, Rah MJ, Manny RE, Berntsen DA, Chitkara M, Kim A, Quinn N. Benefits of Contact Lens Wear for Children and Teens. Eye Contact Lens 2007;33:317-21.

17.             17.       Soni PS, Horner DG, Jimenez L, Ross J, Rounds J. Will young children comply and follow instructions to successfully wear soft contact lenses? Clao J 1995;21:86-92.

18.             18.       Katz J, Schein OD, Levy B, Cruiscullo T, Saw SM, Rajan U, Chan TK, Yew Khoo C, Chew SJ. A randomized trial of rigid gas permeable contact lenses to reduce progression of children's myopia. Am J Ophthalmol 2003;136:82-90.

19.             19.       Horner DG, Soni PS, Salmon TO, Swartz TS. Myopia progression in adolescent wearers of soft contact lenses and spectacles. Optom Vis Sci 1999;76:474-9.

20.             20.       Cho P, Cheung SW, Edwards M. The longitudinal orthokeratology research in children (LORIC) in Hong Kong: a pilot study on refractive changes and myopic control. Curr Eye Res 2005;30:71-80.

21.             21.       Guillon M, Maissa C. Dry eye symptomatology of soft contact lens wearers and nonwearers. Optom Vis Sci 2005;82:829-34.

 

 

 

(p. 49) Treatment Plan: Gaining Some Perspective on Dry Eye Treatment, By Leo Semes, OD, FAAO

 

1.                 Schirmer O (1903) Studien zur Physiologie und Pathologie der Tranenabsonderung

2.                 und Tr~inenabfuhr. Graefe's Arch Clin Exp Ophthalmol 56:197-291.

 

3.                 Thygeson P.  Etiology and treatment of blepharitis.  Arch Ophthalmol 1946; 36: 445-477.

 

4.                 (DEWS 3) Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007; 5: 108-52.

 

5.                 Behrens A, Doyle JJ, Stern L, et.al. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea. 2006; 25: 900-7.

 

6.                 McMonnies CW. Key questions in a dry eye history. J Am Optom Assoc. 1986 Jul;57(7):512-7.

 

7.                 Nichols KK, Nichols JJ, Mitchell GL. The reliability and validity of McMonnies Dry Eye Index. Cornea. 2004 May;23(4):365-71.

 

8.                 Gilbard JP, Rossi SR. Changes in tear ion concentrations in dry-eye disorders. Adv Exp Med Biol. 1994;350:529-33.

 

9.                 Tseng SC. Topical retinoid treatment for dry eye disorders. Trans Ophthalmol Soc U K. 1985;104 ( Pt 4):489-95.

 

10.             Pflugfelder SC, de Paiva CS, Tong L, Luo L, Stern ME, Li DQ. Stress-activated protein kinase signaling pathways in dry eye and ocular surface disease. Ocul Surf. 2005 Oct;3(4 Suppl):S154-7.

 

 

 

(p. 50) Reader and Industry Forum: Evaluating the Efficacy of a New Lubricant Eye Drop, By John L. Schachet, OD

 

1.      International Dry Eye Workshop (DEWS).The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop. Ocul Surface 2007;5:75-92.

2.      Terry M.A. Dry eye in the elderly. Drugs Aging 2001;18:101-7.

3.      Foulks GN. Clinical evaluation of the efficacy of PEG/PG lubricant eye drops with gelling agent (HP-Guar) for the relief of the signs and symptoms of dry eye disease: a review. Drugs Today 2007;43:887-96.

4.      Ketelson HA, Davis J, Meadows DL. Characterization of a Novel Polymeric Artificial Tear Delivery System. The Association for Research in Vision and Ophthalmology (ARVO) 2008;A139.

5.      Moss S., Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118:1264-8.

6.      Lemp MA. Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes. CLAO J. 1995;21:221-32.